• Users Online:352
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 


 
 Table of Contents  
DRUG PROVING
Year : 2008  |  Volume : 2  |  Issue : 1  |  Page : 13-18

Argemone mexicana: A multicentric double blind Homoeopathic Pathogenetic Trial (Drug Proving) carried out by CCRH


1 Drug Proving Research Unit, Kolkata, West Bengal, India
2 Drug Proving Research Unit, Midnapore, West Bengal, India
3 Drug Proving Research Unit, Ghaziabad, Uttar Pradesh, India

Date of Web Publication15-Apr-2014

Correspondence Address:
N R Dey
Central Council for Research in Homoeopathy, 61-65, Institutional Area, Opp. D-Block, Janakpuri, New Delhi-110058
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


Rights and PermissionsRights and Permissions
  Abstract 

Objective : Objective of the study was to elicit the pharmacodynamic response of the drug, Argemone mexicana (prickly poppy) on healthy human volunteers, in non-toxic doses.
Methodology : The drug was proved through a double-blind placebo controlled technique and is a multi-centric study. Trial drug was proved in three potencies (200C, 30C and 6C) on 38 volunteers who were selected and declared apparently healthy during their pre-trial examination by specialists. The volunteers took the three potencies (56 dozes of each potency ) in three stages for a varying period. The symptoms generated during the trial period were noted by the provers and elaborated and cross examined by the Proving Masters. The data obtained from different centers were compiled at proving-cum-data processing cell at CCRH headquarters after de-coding.
Observations : Out of the 25 provers who were on actual drug trial, 18 manifested symptoms. Drug was able to produce symptoms in each potency more or less on every part of the body. Only a few symptoms appeared in more than one prover. Some of the symptoms mentioned in different literatures after fragmentary provings have been reproved.
Conclusion : Symptoms appeared (new and reproved) during the proving trial will add to the literature available on the drug and benefit the research scholars and clinicians. This also needs verification through clinical application in different settings.

Keywords: homoeopathy; homoeopathic pathogenetic trial; drug proving; argemone mexicana


How to cite this article:
Dey N R, Das K C, Rai Y. Argemone mexicana: A multicentric double blind Homoeopathic Pathogenetic Trial (Drug Proving) carried out by CCRH. Indian J Res Homoeopathy 2008;2:13-8

How to cite this URL:
Dey N R, Das K C, Rai Y. Argemone mexicana: A multicentric double blind Homoeopathic Pathogenetic Trial (Drug Proving) carried out by CCRH. Indian J Res Homoeopathy [serial online] 2008 [cited 2019 Aug 21];2:13-8. Available from: http://www.ijrh.org/text.asp?2008/2/1/13/130771

.




 

Top
 
 
  Search
 
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

 
  In this article
   Abstract

 Article Access Statistics
    Viewed1089    
    Printed57    
    Emailed0    
    PDF Downloaded276    
    Comments [Add]    

Recommend this journal


[TAG2]
[TAG3]
[TAG4]